Rate Video

ASCO GI 2021 | Bi-specific antibodies in HER2+ gastric cancer

Hyun C. Chung • 13 Jan 2021

Gastric Cancer Gastrointestinal Cancer Antibodies

CAR-T & Cellular Therapy Immuno-Oncology

Hyun C. Chung, MD, PhD, Yonsei Cancer Center, Seoul, Republic of Korea, provides an overview of ongoing studies in patients with HER2+ gastric cancer, including the use of novel immunotherapy and bi-specific antibodies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

PANTHERA: pembrolizumab, trastuzumab, and chemotherapy in HER2+ advanced gastric cancer

Hyun C. Chung • 13 Jan 2021

Promising results from the gastric cancer cohort of LEAP-005

Hyun C. Chung • 13 Jan 2021

Related Videos

Future therapeutic strategies for HCC

COVID-19 & the management of cancer patients

Alberto F. Sobrero

HER-2 conversion: a phenomenon in trastuzumab resistance

The gut microbiome: role in causing and detecting colorectal cancer